Gilead reports Q4 adjusted EPS $1.86, consensus $1.83

Reports Q4 revenue $7.9B, consensus $7.68B. “Our fourth quarter and full-year results close out a very strong year for Gilead (GILD) overall, including the successful U.S. launch of Yeztugo, the world’s first twice-yearly HIV prevention therapy, and continued growth for Biktarvy and Descovy,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “In 2026, our potential new launches include two cancer therapies and an additional HIV treatment option, and we look forward to building on the launches of Yeztugo and Livdelzi for liver disease. As we continue to increase our positive impact on healthcare, Gilead is well positioned for continued growth in 2026 and beyond.”